BackAvidity Biosciences Overview

Avidity Biosciences Total Liabilities

Track Avidity Biosciences's total liabilities ($58M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$58.26M
55.31% YoYΔ $-72.10M vs prior year quarter

Peer trimmed avg / median

Loading

Avidity Biosciences Total Liabilities History

Loading

Avidity Biosciences vs. peers: Total Liabilities Comparison

Loading

Avidity Biosciences Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Avidity Biosciences (RNA) FAQ

As of the most recent data (March 2026), RNA shows a total liabilities of $58M. That compares with $130M in the prior-year period — down 55.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RNA's total liabilities is now $58M (was $130M) — a 55.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Avidity Biosciences is outperforming or lagging.

Tracking RNA's total liabilities over time shows whether Avidity Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $58M That compares with $130M in the prior-year period — down 55.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has Avidity Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $58M) with ownership activity and broader fundamentals.

Avidity Biosciences's total liabilities is $58M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.